| ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (NCT04669587) | EnhancedBio USA Inc. | 2021-07-26 |
| Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy (NCT04692103) | University of Washington | 2021-07-10 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (NCT03554044) | University of California, San Francisco | 2020-02-05 |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer (NCT03091842) | University of Southern California | 2019-07-29 |
| 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer (NCT03831711) | Andrei Iagaru | 2019-03-19 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer (NCT03723928) | SWOG Cancer Research Network | 2018-09-17 |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer (NCT03377101) | National Cancer Institute (NCI) | 2018-08-07 |
| Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer (NCT03566485) | Vanderbilt-Ingram Cancer Center | 2018-07-10 |
| Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors (NCT03523195) | Fred Hutchinson Cancer Center | 2018-04-18 |
| Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03359954) | M.D. Anderson Cancer Center | 2017-11-16 |
| Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells (NCT03070002) | Northwestern University | 2017-10-19 |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (NCT03213041) | Northwestern University | 2017-09-14 |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer (NCT03042897) | University of Southern California | 2017-09-08 |
| Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (NCT03128619) | Jonsson Comprehensive Cancer Center | 2017-08-02 |
| Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (NCT03132467) | M.D. Anderson Cancer Center | 2017-06-13 |
| Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (NCT02993159) | Northwestern University | 2017-05-31 |
| Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer (NCT02657928) | Mayo Clinic | 2016-07-08 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (NCT02648477) | City of Hope Medical Center | 2016-03-28 |
| MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (NCT02536794) | Northwestern University | 2016-01-14 |
| Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery (NCT02526498) | Rutgers, The State University of New Jersey | 2015-07-15 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (NCT02457910) | Vanderbilt-Ingram Cancer Center | 2015-06-01 |
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) (NCT02186015) | Loyola University | 2015-02-01 |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT02219789) | Mayo Clinic | 2014-12-05 |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer (NCT02202746) | Clovis Oncology, Inc. | 2014-09-09 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (NCT02152943) | M.D. Anderson Cancer Center | 2014-07-17 |
| Broccoli Sprout Extract in Treating Patients With Breast Cancer (NCT01753908) | Roswell Park Cancer Institute | 2013-05-21 |
| Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery (NCT01754519) | Roswell Park Cancer Institute | 2013-05-01 |
| Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091) | Mayo Clinic | 2013-04-09 |
| Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer (NCT01776008) | National Cancer Institute (NCI) | 2013-01-01 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer (NCT01750073) | University of Nebraska | 2012-12-07 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (NCT01697293) | Prescient Therapeutics, Ltd. | 2012-01-01 |
| FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer (NCT01928186) | University of Washington | 2011-09-01 |
| MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT01344031) | National Cancer Institute (NCI) | 2011-04-21 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer (NCT01319539) | National Cancer Institute (NCI) | 2011-04-01 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer (NCT01149356) | National Cancer Institute (NCI) | 2010-10-01 |
| F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy (NCT02149173) | University of Washington | 2010-09-15 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer (NCT00785291) | National Cancer Institute (NCI) | 2008-10-13 |
| Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive (NCT00390455) | National Cancer Institute (NCI) | 2006-09-15 |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen (NCT00118157) | National Cancer Institute (NCI) | 2005-05-01 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer (NCT00338728) | M.D. Anderson Cancer Center | 2003-10-03 |